Bosh sahifaAAVXF • OTCMKTS
add
Abivax SA
Yopilish kursi
11,05 $
Yillik diapazon
10,19 $ - 15,15 $
Bozor kapitalizatsiyasi
603,83 mln EUR
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
EPA
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (EUR) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 3,39 mln | 201,87% |
Joriy xarajat | 43,39 mln | 119,55% |
Sof foyda | -40,82 mln | -57,14% |
Sof foyda marjasi | -1,20 ming | 47,94% |
Har bir ulushga tushum | — | — |
EBITDA | -39,91 mln | -114,56% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (EUR) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 222,32 mln | 94,37% |
Jami aktivlari | 284,49 mln | 66,29% |
Jami passivlari | 158,02 mln | 74,43% |
Umumiy kapital | 126,47 mln | — |
Tarqatilgan aksiyalar | 62,92 mln | — |
Narxi/balansdagi bahosi | 5,50 | — |
Aktivlardan daromad | -35,15% | — |
Kapitaldan daromad | -41,69% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (EUR) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -40,82 mln | -57,14% |
Operatsiyalardan naqd pul | -42,59 mln | -208,62% |
Sarmoyadan naqd pul | 6,73 mln | 886,10% |
Moliyadan naqd pul | 20,16 mln | -65,46% |
Naqd pulning sof oʻzgarishi | -14,81 mln | -133,88% |
Boʻsh pul | -21,07 mln | -45,88% |
Haqida
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
Tashkil etilgan
4-dek, 2013
Sayt
Xodimlar soni
62
